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We examined whether near-infrared light (NIr) treatment (photobiomodulation) saves dopaminergic amacrine cells of the retina
in an acute and a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson disease. For the acute
model, BALB/c mice had MPTP (100mg/kg) or saline injections over 30 hours, followed by a six-day-survival period. For the
chronic model, mice had MPTP (200mg/kg) or saline injections over ﬁve weeks, followed by a three-week-survival period. NIr
treatment was applied either at the same time (simultaneous series) or well after (posttreatment series) the MPTP insult. There
were four groups within each series: Saline, Saline-NIr, MPTP, and MPTP-NIr. Retinae were processed for tyrosine hydroxylase
(TH)immunochemistry,andcellnumberwasanalysed.IntheMPTPgroups,therewasasigniﬁcantreductioninTH+ cell number
compared to the saline controls; this reduction was greater in the acute (∼50%) compared to the chronic (∼30%) cases. In the
MPTP-NIr groups, there were signiﬁcantly more TH+ cells than in the MPTP groups of both series (∼30%). In summary, we
showed that NIr treatment was able to both protect (simultaneous series) and rescue (posttreatment series) TH+ cells of the retina
from parkinsonian insult.
1.Introduction
Manypreviousstudieshavereportedthatmitochondrialdys-
functionisakeycomponentofthepathogenesisofParkinson
disease, a striking motor disorder that develops after a ma-
jor loss of dopaminergic cells in the substantia nigra pars
compacta (SNc) [1]. Hence, treatments that target the
protection and/or enhancement of mitochondrial function
against insult may prove to be useful therapeutic tools. One
such treatment is low intensity light therapy, known also as
photobiomodulation or near infrared light (NIr) treatment.
Previous studies have shown that when exposing cells to
NIr treatment, mitochondrial function and ATP (adenosine-
5 -triphosphate) synthesis are enhanced considerably [2, 3].
Although the precise mechanism is not clear, it has been
reported that NIr treatment beneﬁts overall cell function
(and limits toxic insult) by not only decreasing reactive oxy-
gen and nitrogen species, but also increasing ATP content
and production of speciﬁc cytokines in cells. NIr treatment
is thought to increase electron transfer in the respiratory
chain and activation of photoacceptors, such as cytochrome
oxidase, within the mitochondria [2, 3].
In this study, we sought to extend our previous ﬁndings
on the SNc of MPTP-treated mice [4, 5] by exploring
whetherNIrtreatmentenhancesthesurvivaloftyrosinehyd-
roxylase (TH)+ dopaminergic cells located in the retina. Our
working hypothesis was that, because NIr has almost direct
access through the transparent cornea, lens, and humors the
cells in the retina in vivo, it should be an eﬀective protective
and/or rescue agent, perhaps more so than for the SNc, a
structure located deep in the brain and underneath the
meningeal layers, cranium, skin, and hair. The retinae used2 ISRN Neurology
for this study were from the same animals as those used in
previous acute [4] and chronic [5] MPTP studies exploring
the number of TH+ cells in the SNc.
2.MaterialsandMethods
2.1. Subjects. Male albino BALB/c mice (∼20g; ∼8w e e k s
old; n = 80) were used. They were housed on a 12hr
light/dark cycle with unlimited access to food and water. All
experiments were approved by the Animal Ethics Committee
of the University of Sydney.
2.2. Experimental Design. An acute [4, 6, 7] and a chronic [5,
8] MPTP models were used in this study (Figures 1(a) and
1(b)). In each, NIr treatment was applied either at approxi-
mately the same time (simultaneous) or well after (posttreat-
ment) the MPTP insult (Figures 1(a) and 1(b)). Hence, each
model had two series, simultaneous (Acute-Simultaneous
[Ac-Sim], Chronic-Simultaneous [Ch-Sim]) and posttreat-
ment(Acute-Posttreatment[Ac-PT],Chronic-Posttreatment
[Ch-PT]).Withineachofthese,therewerefourexperimental
groups, where mice received intraperitoneal injections of
either MPTP or saline, combined with NIr treatments or
not (Figures 1(a) and 1(b)). The diﬀerent groups were: (1)
Saline (n = 21): saline injections with no NIr (2) Saline-NIr
(n = 19): saline injections with NIr (3) MPTP (n = 22):
MPTPinjectionswithnoNIr(4)MPTP-NIr(n = 18):MPTP
injections with NIr.
For the acute model, four (25mg/kg injections; total of
100mg/kg per mouse) MPTP or saline injections were made
overa30hrperiod.Afterthelastinjection,micewereallowed
to survive for six days. For the chronic model, mice had
ten injections of MPTP (20mg/kg per injection; total of
200mg/kg per mouse) or saline combined with probenecid
(250mg/kg; decreases renal excretion of MPTP and hence
maintains the eﬀects of toxin during injection intervals),
approximately three and a half days apart, over a ﬁve-week-
period. After the last injection, mice were allowed to survive
for three weeks. For both models, the dose regimes and
survival periods were similar to those used by previous stu-
dies, including our own [4–11]. The survival periods were
aimed to allow suﬃcient time for the MPTP to impart
toxicity upon the dopaminergic cells. We did not observe
any behavioural deﬁcits in the mice after MPTP injection,
although in some instances, the mice became quiescent im-
mediately afterwards. However, these mice soon returned to
normal activity, eating and grooming, within the next few
hours.
FortheNIrtreatment,miceintheMPTP-NIrandSaline-
NIr groups of each model (acute and chronic) were treated
with 670nm light from a light-emitting device (Quantum
Devices WARP 10) as described previously [4, 5]. Brieﬂy, for
the simultaneous series of both models, mice had NIr treat-
ment (the LED was held just above the mouse’s head and in
full view of their eyes and one cycle of 90secs, estimated at
0.5Joule/cm2,wasapplied)[4] ∼15minsaftereachMPTPor
saline injection. Hence, for each MPTP insult there would be
almost immediate potential therapeutic application. For the
posttreatment series of both models, mice had NIr treatment
approximately four days after the last injection. For the acute
model, these treatments were spread over last two days of
the survival period (total of four cycles), while for the chro-
nic model, they were spread over three weeks (total of ten
cycles). Hence, for this series, potential therapeutic applica-
tion occurred well after the MPTP insult. For both models,
these NIr treatment regimes were similar to that used by pre-
vious studies, in particular, those reporting changes after
transcranial irradiation [4, 5, 12–17]. No behavioural or
structural(e.g.,inglobe)deﬁcitswereevidentafterNIrtreat-
ment.TheLEDgeneratedverylittleheat,anditdidnotcause
any visible discomfort to the mice.
2.3. Immunohistochemistry. Following the survival periods,
mice were anaesthetised with an intraperitoneal injection of
sodium pentobarbital (60mg/mL). They were then perfused
transcardially with 0.1M phosphate-buﬀered saline (PBS;
pH 7.4), followed by 4% buﬀered formaldehyde. The retinae
were removed and postﬁxed for ∼20mins in the same solu-
tion. Next, retinae were dissected free from other structures
in the globe as wholemounts [18]. A deep cut was made in
superior retina for orientation. Retinae were immersed in a
solution of 1% Triton (Sigma) and 10% normal goat serum
in PBS at room temperature for 1hr. They were then in-
cubated in antityrosine hydroxylase (TH; Sigma, 1:500) for
∼48hrs (at 4◦C), followed by biotinylated anti-rabbit IgG
(Bioscientiﬁc; 1:200) for ∼4hrs (at room temperature), and
then Extravidin-FITC complex (Sigma; 1:200) for ∼2hrs
(at room temperature). Between each incubation, retinae
were washed in three changes of PBS. Retinae were mounted
onto glass slides, coverslipped using Fluoromount (Sigma),
and viewed under a ﬂuorescence microscope. We found the
FITC method far more sensitive than the peroxidase (and
diaminobenzidine; DAB) method; FITC revealed the TH+
somata, together with their intricate dendritic plexus, more
consistently across the entire retinal wholemount, from cen-
tral to peripheral regions. The FITC method was certainly
stableanddurableenoughforustoundertakeacompletecell
count and area analysis of each retina. For controls, sections
were processed as described above, except that there was
no primary antibody used. These control sections were im-
munonegative.
2.4. Analysis. Each retina was scanned systematically under
the ﬂuorescence microscope and the number of TH+ cells
andretinalareawerecalculatedwiththeaidofastereological
programme (StereoInvestigator, MBF Science). Every TH+
cell was plotted and total number was recorded; for the
areas, the boundaries of each retina were traced and the
programme calculated the area (mm2). For comparisons
between groups (using GraphPad Prism programme), a
oneway ANOVA test (F test; P value) was performed with
a Tukey-Kramer multiple comparison test (q test; P value).
Schematic diagrams and digital images were constructed
using Adobe Photoshop and Microsoft PowerPoint pro-
grammes.ISRN Neurology 3
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Figure 1: Outline of the diﬀerent experimental groups used in this study, namely: Saline, Saline-NIr, MPTP, and MPTP-NIr, in either the
simultaneous (a) or posttreatment (b) series of the acute and chronic models. Photomicrographs of TH+ amacrine cells in retinal
wholemounts of the superior temporal region (c) and of the retinal edges ((d), (e)). The latter reveals the location of the TH+ somata and
dendrites within the diﬀerent layers. Most TH+ somata were located in the inner layers of the inner nuclear layer (c); very few were located
in the ganglion cell layer (e). All images from Saline group of Ac-Sim case. Scale bars = 100µm.
3. Results
The results that follow will be presented in four main parts:
(i)morphology,(ii)retinalareas,(iii)number,and(iv)topo-
graphy.
3.1. Morphology. Conﬁrming previous studies [10, 19, 20],
TH immunoreactivity in the mouse retina was seen in ama-
crine cells with large oval- or triangular-shaped somata
(Figure 1(c)) located mainly in the inner part of the inner
nuclear layer (Figure 1(d)); only one or two cells per retina4 ISRN Neurology
were ever seen in the ganglion cell layer (Figure 1(e)). Most
somata had one to two labelled primary dendrites that for-
med a rich overlapping plexus (Figure 1(c)) found in the
innerplexiformlayer(Figures1(d)and1(e))[21].Ingeneral,
the morphology of TH+ amacrine cells was similar in all
groups.
3.2. Retinal Areas. The graph in Figure 2(a) shows the
retinal areas in the diﬀerent experimental groups in each
of the Acute-Simultaneous (Ac-Sim), Acute-Posttreatment
(Ac-PT), Chronic-Simultaneous (Ch-Sim), and Chronic-
Posttreatment (Ch-PT) cases. Overall, these values were
similar to those reported previously for the retinal area of
mice (∼15mm2)[ 19]. We found no signiﬁcant diﬀerence
between the retinal areas of the diﬀerent cases (ANOVA test:
F = 1.1; P = 0.4), indicating that our MPTP or NIr treat-
ment had no impact on retinal area.
3.3. Number. The graph in Figure 2(b) shows the total num-
ber of TH+ cells in the retinae of the four experimental
groups in each of the Ac-Sim, Ac-PT, Ch-Sim, and Ch-
PT cases. Overall, the variations in number were signiﬁcant
(ANOVA test: F = 8.5; P<0.0001). A more detailed analysis
of TH+ cell number in the diﬀerent cases will be considered
in the paper.
For the Saline and Saline-NIr groups, TH+ cell number
in the diﬀerent cases were not signiﬁcantly diﬀerent (Tukey-
Kramer test; P>0.05). These values were comparable to
those reported for normal mice by previous studies [10, 11,
19].
For the MPTP groups, TH+ cell number was reduced
compared to the saline groups in all the cases. These reduc-
tions were signiﬁcant (Tukey-Kramer test) in each of the
Ac-Sim (P<0.001 Figure 2(b)†), Ac-PT (P<0.001;
Figure 2(b)†), Ch-Sim (P<0.01; Figure 2(b)∧), and Ch-PT
(P<0.01; Figure 2(b)∧)c a s e s .T h er e d u c t i o ni nT H + cell
number was greater in the acute (∼50%) than in the chronic
(∼30%) cases (Figure 2(b)), and these diﬀerences were
signiﬁcant (P<0.05). Conversely, no signiﬁcant diﬀerences
(P>0.05) were found between the acute and between the
chronic cases.
The number of TH+ cells in the substantia nigra pars
compacta (SNc), from the same brains where the retinae
were taken from, has been analysed too and full details of the
results were published [4, 5]. Brieﬂy, there was substantial
TH+ cell loss in the SNc in both our acute (∼60%) and
chronic (∼45%) MPTP models. In addition, there were also
fewer TH+ terminals in the striatum, the major termination
zone of the SNc axons, of the MPTP groups compared to the
others. Hence, these features, together with the results on the
retinae described above, conﬁrm that our MPTP regime was
eﬀective.
In the MPTP-NIr groups, TH+ cell number was higher
than in the MPTP groups in all the cases (∼30%). These in-
creases were signiﬁcant (Tukey-Kramer test) in the Ac-PT
(P<0.01; Figure 2(b)∧), Ch-Sim (P<0.01; Figure 2(b)∧),
and Ch-PT (P<0.05; Figure 2(b)∗) cases, although not in
the Ac-Sim case (P>0.05; Figure 2(b)). When compared to
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Figure 2: Graphs showing (a) the areas and (b) the number of TH+
amacrine cells in the retinae in the four experimental groups in the
diﬀerentcases(diﬀerentshadedcolumns).Columnsshowthemean
± standard error of the total number of cells in each case. †Rep-
resents P<0.001, ∧represents P<0.01 and ∗represents P<0.05
signiﬁcant diﬀerence in cell number; these symbols on the columns
of the MPTP group represent diﬀerences from the Saline group
of each case, while symbols on the MPTP-NIr group represent
diﬀerences from the MPTP group of each case. There were clear
increases in TH+ cell number in the MPTP-NIr group compared to
the MPTP group in all cases, particularly the Ac-PT, Ch-Sim, and
Ch-PT.
the saline groups, TH+ cell number in the MPTP-NIr groups
was reduced signiﬁcantly only in the Ac-Sim case (Tukey-
Kramer test; P>0.01). In all the other cases, and unlike
in the MPTP groups, TH+ cell number is not signiﬁcantly
diﬀerent (P>0.05) to the saline groups (Figure 2(b)).
In summary, TH+ cell number in the MPTP groups was
reduced from the saline groups, particularly in the acute
cases. In the MPTP-NIr groups, there were more TH+ cellsISRN Neurology 5
compared to the MPTP groups in all cases, although to a
lesser extent in the Ac-Sim case.
3.4. Topography. We examined the distribution of TH+ cells
in the diﬀerent cases as to determine whether the MPTP or
NIr treatment aﬀected one retinal region more than another.
Figure 3 shows maps and photomicrographs of TH+ cells in
the representative retinae of Saline (Figures 3(a) and 3(b)),
Saline-NIr (Figures 3(c) and 3(d)), MPTP (Figures 3(e) and
3(f),andMPTP-NIr(Figures3(g)and3(h)groupsoftheAc-
Sim case (this case shown because it had the most change
after MPTP treatment). In all groups, TH+ cells were found
in all retinal regions, but with more tendency to be located
in superior and temporal retina [19, 21]. There was no par-
ticular region of retina that was aﬀected greatly by either
MPTP or NIr treatment, although there were fewer cells in
the MPTP groups (see above in this case). In general, these
patterns of distribution in each group were similar in the
diﬀerent cases.
4. Discussion
We had three main ﬁndings. First, there were fewer TH+
amacrine cells in the MPTP groups compared to the saline
controls, particularly in the acute cases. Second, the magni-
tude of TH+ celllossafterMPTPinsultwasnotassubstantial
as that seen in the SNc. Third, and importantly, there were
more TH+ cells in the MPTP-NIr compared to the MPTP
groups. Each of these issues will be discussed in this paper.
First, a comparison with previous studies will be considered.
4.1. Comparison with Previous Studies. Previous studies have
shown that NIr treatment oﬀers in vivo protection to retinal
photoreceptor cells against degeneration after exposure of
either excessive illumination [22, 23] or methanol toxin [24].
We extend these ﬁndings by showing that NIr treatment
protects another type of retinal cell, the TH+ amacrine cell,
against MPTP insult. There have been many studies showing
lower dopamine levels and TH immunoreactivity in the
retinae of parkinsonian patients [25, 26]a n dM P T P - t r e a t e d
animals [10, 23, 27–30] compared to controls. Our present
results support these ﬁndings. By contrast, Nagel and colle-
agues [11] using comparable dose regimes (150mg/kg) and
survival periods (7–14 days) have reported minimal loss of
TH+ cells in the retinae of MPTP-treated mice. The reasons
for these diﬀerences are not clear, although our results are
similar in that TH+ cell loss was less in the retina than in the
SNc.
4.2. MPTP Toxicity in the Retina and Comparison with SNc.
Although some of our TH+ cell loss may be due to transient
TH expression after MPTP insult [10], we suggest that the
majorityofthelosswasduetocelldeath[6,9,31].Manypre-
vious studies have shown that a loss of TH reﬂectsoverallcell
survival. For example, MPTP insult has been shown to aﬀect
TH expression and then, after a prolonged period, generate
cell death [31]. Furthermore, MPTP insult results in fewer
Nissl-stained (and TH+) cells in the SNc indicating cell death
[6, 9]. Nevertheless, whether transient expression or death
(apoptotic or necrotic [32]), the important aspect of our
study was that NIr treatment saved cellular TH expression
during a period when MPTP treatment alone would have
abolished.
T h em a g n i t u d eo fT H + amacrine cell loss after MPTP
insult was greater in the acute cases (∼50%) than in the
chronic ones (∼30%). Our chronic model delivered double
the dose of MPTP (200 versus 100mg/kg), but it was not as
damaging to the amacrine cells as the acute insult delivered
over a much shorter time period, 30 hours as against 5
weeks. Such ﬁndings have been reported previously by many
studies. In the SNc, for example, acute insults generate up to
70% cell loss, while the chronic insults generate only about
50% [33, 34].
In the SNc, the reduction in TH+ cell number was ∼15%
greater than in the retina in both models [4, 5], indicating
that the SNc cells are less resistant to MPTP insult than the
retinal cells. Previous studies have reported similar ﬁndings,
that the SNc cells (ventral sector) are more vulnerable to
parkinsonian insult (i.e., MPTP insult, 6 hydroxydopamine
lesion, idiopathic Parkinson disease) than other dopaminer-
gic cell groups, for example, those in the ventral tegmental
area, retrorubral ﬁeld, dorsal sector of the SNc [1, 35, 36],
zona incerta-hypothalamus, and periaqueductal grey matter
[4, 5]. The factors that render retinal dopaminergic cells
more resistant to MPTP insult than those in the SNc are not
clear. For other dopaminergic cells it has been suggested that
their levels of calbindin expression [35], dopamine trans-
porter molecule (DAT) [37], and/or neuromelanin [38]m a y
contribute to their greater resistance to toxic insult. The
dopaminergic amacrine cells do not contain neuromelanin,
but they have been reported to be calbindin+ [39]a n d
DAT+ [37]. These two factors may contribute to their greater
survival in the MPTP groups. We speculate also that mela-
tonin, a hormone with antioxidant properties released by
the nearby photoreceptors [40], has a role in rendering the
amacrine cells more resistant to MPTP insult (see below).
The issue of why some dopaminergic amacrine cells were
more resistant to MPTP toxicity than others is not clear; the
surviving cells appeared healthy and had no obvious change
in their morphology (see Results). Perhaps these surviving
cells contained more calbindin [39] and/or DAT [37] than
thosethathadundergonecelldeath,andthatthesemolecules
served as neuroprotectants.
4.3. Patterns of Cell Protection and Rescue by NIr Treatment.
There were more TH+ cells in the MPTP-NIr compared to
the MPTP groups in all the cases, although to a lesser extent
in the Ac-Sim case. There are three issues more to consider
regarding this ﬁnding. First, despite the diﬀerent types of
intervening body tissue, whether transparent membranes of
the globe or hair, skin, bone, and meninges, NIr treatment
mitigated the MPTP insult just as eﬀectively in the retina
(∼30%) and SNc (∼35%) [4, 5]. Second, NIr treatment
saved about the same number of retinal cells regardless of
the nature of the parkinsonian insult, whether acute (∼30%)
or chronic (∼25%). Third, NIr treatment saved about the6 ISRN Neurology
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Figure 3: Schematic diagrams of maps ((a), (c), (e), (g)) and photomicrographs ((b), (d), (f), (h)) of TH+ amacrine cells in the retinae of
Saline ((a), (b)), Saline-NIr ((c), (d)), MPTP ((e), (f)), and MPTP-NIr ((g), (h)) groups of the Ac-Sim case (this case shown because it had
the most change after MPTP treatment). The photomicrographs are of a midregion of superior temporal retina in each case. In the saline
control groups ((a)–(d)), TH+ cells were distributed relatively uniformly across the retina, but with a slight concentration in superior and
temporal retina. In the MPTP and MPTP-NIr groups ((e)–(h)), there was no particular region of retina that was aﬀected particularly after
MPTP (or NIr) treatment. Scale bar = 100µm.ISRN Neurology 7
same number of retinal cells whether applied at the same
time (simultaneous) or well after (posttreatment) the MPTP
insult (25–30%). NIr treatment was hence protective to
healthy cells against insult, but also rescued damaged cells
after the insult. Most of the protection was likely to have
occurredinthesimultaneousseries,whilethemajorityofthe
rescuing in the posttreatment series. A comparable pattern
of protection and rescue has been noted in the SNc after NIr
treatment [4, 5] and also after deep brain stimulation of the
subthalamic nucleus in MPTP-treated monkeys [9].
The precise mechanism(s) that saved the TH+ amacrine
cells from degeneration is not known. Many authors have
suggested that NIr triggers intrinsic trophic factors that en-
hance cell survival, for example, by increasing ATP produc-
tion and reducing reactive oxygen species in the mitochon-
dria (see Introduction). In addition, we suggest that NIr
treatment stimulated the local release of melatonin, a power-
fulantioxidantandcellsavingagent[41,42],fromtheretinal
photoreceptors, that in turn, enhanced the survival of the
dopaminergic amacrine cells [5, 43]. The local melatonin
may have promoted mitochondrial activity and reduced
oxidative stress in the amacrine cells, helping them survive
the MPTP insult. Future studies may examine the eﬀects of
NIr treatment on retinal melatonin levels in normal and in
parkinsonian cases.
Abbreviations
Ac-Sim: Acute-simultaneous
Ac-PT: Acute-posttreatment
ATP: Adenosine-5 -triphosphate
Ch-Sim: Chronic-simultaneous
Ch-PT: Chronic-posttreatment
DAT: Dopamine transporter molecule
GCL: Ganglion cell layer
INL: Inner nuclear layer
IPL: Inner plexiform layer
LED: Light emitting device
MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NIr: Near-infrared light
PBS: Phosphate buﬀered saline
SNc: Substantia nigra pars compacta
TH: Tyrosine hydroxylase.
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